A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
Authors
Keywords
Focal adhesion kinase, Proline-rich tyrosine kinase-2, Dose-escalation study, VS-6063, Defactinib
Journal
INVESTIGATIONAL NEW DRUGS
Volume 33, Issue 5, Pages 1100-1107
Publisher
Springer Nature
Online
2015-09-03
DOI
10.1007/s10637-015-0282-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
- (2013) Georgia Konstantinidou et al. Cancer Discovery
- 400 FAK Inhibitor VS-4718 Attenuates Breast Cancer Stem Cell Function and Inhibits Tumor Growth in Vivo
- (2012) Q. Xu et al. EUROPEAN JOURNAL OF CANCER
- 610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma
- (2012) J.C. Soria et al. EUROPEAN JOURNAL OF CANCER
- Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors
- (2012) Jeffrey R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacologic Blockade of FAK Autophosphorylation Decreases Human Glioblastoma Tumor Growth and Synergizes with Temozolomide
- (2012) V. M. Golubovskaya et al. MOLECULAR CANCER THERAPEUTICS
- Focal Adhesion Kinase as a Cancer Therapy Target
- (2011) Vita M. Golubovskaya Anti-Cancer Agents in Medicinal Chemistry
- Compensatory Function of Pyk2 Protein in the Promotion of Focal Adhesion Kinase (FAK)-null Mammary Cancer Stem Cell Tumorigenicity and Metastatic Activity
- (2011) Huaping Fan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis
- (2010) Xiaofeng Zhao et al. ADVANCED DRUG DELIVERY REVIEWS
- Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer
- (2010) Alexander Schultze et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions
- (2010) M. D. Schaller JOURNAL OF CELL SCIENCE
- The role of focal adhesion kinase in tumor initiation and progression
- (2010) Paolo P. Provenzano et al. Cell Adhesion & Migration
- Targeting focal adhesion kinase signaling in tumor growth and metastasis
- (2009) Joerg Schwock et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Targeting Pyk2 for therapeutic intervention
- (2009) Christopher A Lipinski et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271
- (2008) W. G. Roberts et al. CANCER RESEARCH
- Focal Adhesion Kinase: Targeting Adhesion Signaling Pathways for Therapeutic Intervention
- (2008) J. T. Parsons et al. CLINICAL CANCER RESEARCH
- Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK
- (2008) Sara M. Weis et al. JOURNAL OF CELL BIOLOGY
- Functional inactivation of NF2/merlin in human mesothelioma
- (2008) Claudio Thurneysen et al. LUNG CANCER
- Focal adhesion kinase as a regulator of cell tension in the progression of cancer
- (2007) Robert W. Tilghman et al. SEMINARS IN CANCER BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now